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ORIGINAL ARTICLE
Effects of Sodium–Glucose Co-transporter 2 Inhibition
with Empaglifozin on Renal Structure and Function in Non-diabetic
Rats with Left Ventricular Dysfunction After Myocardial Infarction
Salva R. Yurista1 & Herman H. W. Silljé1 & Harry van Goor2 & Jan-Luuk Hillebrands2 & Hiddo J. L. Heerspink3 &
Luiz de Menezes Montenegro1 & Silke U. Oberdorf-Maass1 & Rudolf A. de Boer1 & B. Daan Westenbrink1
# The Author(s) 2020
Abstract
Background The use of sodium–glucose co-transporter 2 inhibitors (SGLT2i) is currently expanding to cardiovascular risk
reduction in non-diabetic subjects, but renal (side-)effects are less well studied in this setting.
Methods Male non-diabetic Sprague Dawley rats underwent permanent coronary artery ligation to induce MI, or sham surgery.
Rats received chow containing empagliflozin (EMPA) (30 mg/kg/day) or control chow. Renal function and electrolyte balance
were measured in metabolic cages. Histological and molecular markers of kidney injury, parameters of phosphate homeostasis
and bone resorption were also assessed.
Results EMPA resulted in a twofold increase in diuresis, without evidence for plasma volume contraction or impediments in renal
function in both sham and MI animals. EMPA increased plasma magnesium levels, while the levels of glucose and other major
electrolytes were comparable among the groups. Urinary protein excretion was similar in all treatment groups and no
histomorphological alterations were identified in the kidney. Accordingly, molecular markers for cellular injury, fibrosis, inflam-
mation and oxidative stress in renal tissue were comparable between groups. EMPA resulted in a slight increase in circulating
phosphate and PTH levels without activating FGF23–Klotho axis in the kidney and bone mineral resorption, measured with
CTX-1, was not increased.
Conclusions EMPA exerts profound diuretic effects without compromising renal structure and function or causing significant
electrolyte imbalance in a non-diabetic setting. The slight increase in circulating phosphate and PTH after EMPA treatment was
not associated with evidence for increased bone mineral resorption suggesting that EMPA does not affect bone health.
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TGF-β1 Transforming growth factor beta-1
α-SMA Alpha-smooth muscle actin
IL-6 Interleukin 6
IL-1β Interleukin 1 beta
NOX4 NADPH oxidase 4
NRF2 Nuclear factor (erythroid-derived 2)-like 2
RAAS Renin–angiotensin–aldosterone system
MRAs Mineralocorticoid receptor antagonists
EF Ejection fraction
AKI Acute kidney injury
NaPi Sodium–phosphate cotransporter
Introduction
Sodium–glucose co-transporter 2 inhibitors (SGLT2i) reduce
cardiovascular (CV) events and prevent heart failure (HF)
hospitalizations when given to diabetic subjects with either
established CV disease or with multiple risk factors for CV
disease [1–3]. Furthermore, SGLT2 inhibitors also appear to
slow the progression of diabetic kidney disease in patients
with type 2 diabetes mellitus (T2D) [4–6]. On the other hand,
it has also been suggested that SGLT2 inhibitors promote bone
mineral reabsorption and may increase fracture risk in these
patients [7–9].
The substantial reduction in HF hospitalizations observed
in patients with T2D have led to the hypothesis that these
drugs could also be beneficial in non-diabetic patients.
Indeed, we and others have recently demonstrated that the
SGLT2i EMPA improves cardiac function and ameliorates
cardiac remodelling in non-diabetic animals with HF after a
large myocardial infarction (MI) [10, 11]. The effects of
SGLT2i on clinical outcomes are also currently under inves-
tigation in several phase 3 clinical trials that include diabetic
and non -d i abe t i c HF pa t i en t s (NCT03057977 ,
NCT03057951, NCT03036124, NCT03619213). Recently,
the Dapagliflozin And Prevention of Adverse-outcomes in
Heart Failure (DAPA-HF, NCT03036124) trial revealed that
the SGLT2i dapagliflozin reduced the risk of worsening heart
failure or cardiovascular mortality, regardless of the presence
or absence of diabetes [12]. Importantly, dapagliflozin did not
appear to compromise renal function [12].
SGLT2i have potent diuretic properties, which may partial-
ly explain their beneficial effects on HF hospitalisations [13,
14]. Nevertheless, the diuretic effects of SGLT2i could also
limit the use of SGLT2i in HF patients without T2D. While
diuretics are recommended to alleviate congestion in HF pa-
tients, their side effects include plasma volume contraction,
electrolyte imbalance, renal dysfunction and even kidney in-
jury [15, 16]. As renal dysfunction is strongly associated with
impaired outcome in HF patients [16–18], careful titration of
diuretics is of paramount importance in HF [16]. While the
effects of SGLT2i on renal function are well described in
patients with T2D, little is known about the renal effects of
SGLT2i in the non-diabetic context. We therefore aimed to
determine the effects of empagliflozin (EMPA) on renal struc-
ture and function in non-diabetic rats with LV dysfunction
after MI, as this is a realistic clinical scenario if not now, likely
in the near future.
Methods
The current analysis represents a renal substudy of a recently
published article [10]. We refer to this publication for detailed
description of the methods and the cardiometabolic effects.
Animals
The study was performed in male non-diabetic Sprague
D aw l e y r a t s w e i g h i n g 2 5 0 – 2 8 0 g ( E n v i g o ,
The Netherlands). Animals were fed ad libitum and housed
conventionally in groups of two to four rats with 12:12 h
light–dark cycles. The study was approved by the local
Animal Ethics committee (IvD number 16487-02-001) and
we followed ARRIVE guidelines when reporting this study
[19].
Myocardial Infarction Surgery
Rats were randomized to HF or sham surgery under isoflurane
anaesthesia. HF was induced by permanent ligation of the
proximal portion of the left coronary artery as previously de-
scribed [20, 21]. Sham-operated rats underwent the same pro-
cedure but without coronary ligation.
Investigational Drug
Empagliflozin (BI 10773) was mixed with standard rat chow
(R/M-H V1534-70, Ssniff, Germany) in a final concentration
of 200 mg/kg intended to reach an average dose of 30 mg/kg/
day.
Experimental Protocol
As described previously, this study represents a renal-oriented
substudy of a recently published cohort of non-diabetic rats
with LV dysfunction after MI [10]. Rats were treated with
EMPA or chow starting either 2 days before surgery
(EMPA-early) or 2 weeks after surgery (EMPA-late). After
10 weeks of treatment with EMPA or vehicle, rats were anaes-
thetized, blood was drawn (either anti-coagulated with EDTA
or sodium heparin) and the organs were rapidly excised.
Kidney tissues were sectioned transversally and processed
for immunohistochemistry or snap-frozen for molecular
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analysis. Rats with an infarct size of less than 15% were ex-
cluded from analysis.
Metabolic Cage
Two weeks before termination, rats were placed in metabolic
cages to monitor 24-h water and food intake and 24-h urine
collection, as described [10]. After 24-h, blood samples were
drawn from tail vein and plasma was collected. Plasma and
urine were stored at − 80 °C for later analysis.
Histology
The kidneywas sectioned transversally, fixed by immersion in
4% buffered formaldehyde solutions for 48 h (Klinipath,
The Netherlands) and subsequently embedded in paraffin ac-
cording to standard procedures. Paraffin sections were stained
with periodic acid Schiff (PAS) as described before [22].
Mesangial matrix expansion, focal glomerulosclerosis and in-
terstitial fibrosis were evaluated histomorphologically by an
experienced renal pathologist (HvG).
Blood Measurements
Upon sacrifice, 8 ml of blood was drawn from the abdominal
aorta and urine was obtained from the bladder. Routine plasma
biochemistries (urea, creatinine, phosphorus, magnesium, cal-
cium, uric acid) were determined by Roche COBAS (Roche
Diagnostics, Germany). Plasma parathyroid hormone (PTH)
concentration was analysed using Immutopics intact PTH
ELISA kit 60-2500 (San Clemente, USA) according to the
manufacturer’s protocol. Fibroblast growth factor 23 (FGF-
23) level was measured in plasma using LSBio intact FGF-
23 ELISA kit according to the manufacturer’s protocol
(Seattle, USA). Cross-linked C-terminal telopeptide of type I
collagen (CTX-1) concentration in plasma was measured
using RatLaps™ EIA kit (IDS, Boldon, UK).
Urine Measurements
Routine urinalysis (total protein, creatinine and phosphorus)
were determined on the Roche COBAS (Roche Diagnostics,
Germany). Creatinine clearance, as an estimation for glomer-
ular filtration rate, was calculated from 24 h urinary and plas-
ma creatinine levels as previously described [10, 22].
Quantitative Real-Time PCR
RNA was extracted from the kidney using TRIzol reagent
(Invitrogen Corp., USA) and cDNA was synthesized by
Quant iTec t Reverse Transcr ip t ion Ki t (Qiagen ,
The Netherlands) as previously described [10] following man-
ufacturer’s protocol. Relative gene expressions were
determined by a qRT-PCR (Bio-Rad Lab, The Netherlands).
36B4 reference gene was used to correct all measured mRNA
expression. Primer sequences can be found in the online sup-
plementary Table S1.
Statistical Analysis
Data are presented as means ± standard errors of the mean
(SEM). To compare normally distributed parameters, one-
way analysis of variance (ANOVA) followed by Tukey’s post
hoc test was used. When data were not normally distributed, a
non-parametric Kruskal–Wallis test followed by a Mann–
Whitney U test with correction for multiple comparisons
was used. To compare EMPA and vehicle treatment indepen-
dent of treatment allocation, an independent t test or a Mann–
WhitneyU test was used, where appropriate. Differences were
considered significant at p < 0.05. IBM SPSS Statistics for
Windows, Version 23.0 (IBM Corp, USA) was used to per-
form all statistical analysis.
Results
A total of 140 rats were randomized toMI or sham surgery, 47
rats died during the surgical procedure and 20 rats with an
infarct < 15% of the left ventricle were excluded from analy-
sis, leaving a total of 73 rats for the current analysis. The final
group sizes were 8 for the sham-vehicle (Sham-Veh) group, 19
for sham-EMPA group, 22 for MI-vehicle (MI-Veh) group
and 24 for MI-EMPA group.
General and Cardiac Effects of EMPA
A detailed description of the effects of EMPA on food and
fluid intake as well as cardiac structure and function in this
cohort have been recently published [10], as a reference they
are depicted in Table 1. Food intake was comparable between
vehicle and EMPA-treated groups (Table 2), resulting in an
average daily intake of 30 mg/kg/day of EMPA. While the
size of the MI was comparable between the vehicle and the
EMPA treatment groups, EMPA resulted in a marked im-
proved cardiac function and attenuated echocardiographic
and histological indices for cardiac remodelling (Table 1).
Effects of EMPA on Renal Structure
To investigate the effect of EMPA on the renal structure, wet
weight of the kidney and 24-h protein excretion were mea-
sured and kidney sections stained with PAS were analysed.
The relative wet kidney weight was slightly increased in sham
and MI animals treated with EMPA compared to vehicle-
treated rats (Fig. 1a). Daily protein excretion did not differ
among the groups, indicating that EMPA did not cause
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proteinuria (Fig. 1b). Furthermore, histomorphological chang-
es were not observed in sham and MI animals treated with
EMPA or vehicle (Fig. 1c).
To assess molecular markers for kidney damage, mRNA
expression of markers for kidney injury, fibrosis, inflamma-
tion and oxidative stress were determined. The cellular injury
markers kidney injury molecule-1 (KIM-1), tissue inhibitor of
metalloproteinases 2 (TIMP2) and cystatin C, that is used as a
marker to estimate GFR, as well as the kidney fibrosis markers
transforming growth factor beta-1 (TGF-β1), alpha-smooth
muscle actin (α-SMA) and galectin-3 were comparable be-
tween groups (Fig. 2a, b). Moreover, the inflammatory
markers interleukin 6 (IL-6) and interleukin 1 beta (IL-1β)
and the oxidative stress markers NADPH oxidase 4 (NOX4)
and the nuclear factor (erythroid-derived 2)-like 2 (NRF2)
were also comparable (Fig. 2c, d). Taken together, our results
indicate that the small increase in kidney weight observed in
our cohort was not associated with evidence of structural
damage to the kidney. The increase in kidney weight is prob-
ably caused by non-pathological fluid accumulation that was
removed by alcohol solutions in dehydration step.
Effects of EMPA on Electrolytes and Renal Function
EMPA resulted an increased in sodium and glucose excretion
as well as a twofold increase in urine production (Table 2).
Fluid intake was also twofold higher in EMPA-treated sham
and MI groups and there was no evidence for plasma volume
contraction as evidenced by comparable haematocrit levels
(Table 2) and plasma urea concentrations (Fig. 3a).
Similarly, creatinine clearance was comparable between the
groups (Fig. 3b). No changes were observed in plasma con-
centrations of glucose, sodium and potassium (Table 2).
Plasma calcium and uric acid (Fig. 3c, d) were also compara-
ble between EMPA and vehicle-treated groups. EMPA has
been shown to increase magnesium levels in patients with
Table 1 Cardiovascular characteristics
Parameters Sham-Veh Sham-EMPA MI-Veh MI-EMPA
MI size (%) 0 0 31.3 ± 1.5 33.5 ± 2.0
VWs/TL (mg/mm) 30.8 ± 0.4 30.7 ± 0.6 33.9 ± 0.5# 30.7 ± 0.6*
LVEF (%) 73 ± 3 75 ± 2 43 ± 2# 54 ± 2*
% fibrosis 4.8 ± 1.7 3.95 ± 0.9 19.5 ± 2.5# 10.1 ± 0.6*
Cardiomyocyte CSA (μm2) 447.9 ± 158.3 450.4 ± 103.3 814.4 ± 49.0# 629.1 ± 28.6*
SBP (mmHg) 114 ± 4 116 ± 4 118 ± 4 109 ± 9
DBP (mmHg) 81 ± 4 82 ± 4 85 ± 3 78 ± 8
ANP mRNA (fold change) 1.00 ± 0.18 1.33 ± 0.24 6.51 ± 0.84# 3.67 ± 0.61*
β-MHC/α-MHC mRNA ratio (fold change) 1.00 ± 0.18 1.04 ± 0.07 1.98 ± 0.18# 1.16 ± 0.07*
Data are presented as means ± SEM
Veh vehicle, EMPA empagliflozin,MImyocardial infarction, VW/TL ventricular weight/tibia length, LVEF LVejection fraction,CSA cross-sectional area,
SBP systolic blood pressure, DBP diastolic blood pressure, ANP atrial natriuretic peptides, β-MHC myosin heavy chain isoform beta, α-MHC myosin
heavy chain isoform alpha
*p < 0.05 vs. MI-Veh; # p < 0.05 vs. Sham-Veh
Table 2 General characteristics
of rats with LV dysfunction and
sham-operated animals
Parameters Sham-Veh Sham-EMPA MI-Veh MI-EMPA
Water intake (ml/24 h) 33.7 ± 0.9 59.8 ± 1.3# 31.9 ± 0.6 63.4 ± 1.3*
Food intake (g/24 h) 32.9 ± 0.3 33.3 ± 0.3 32.9 ± 0.3 33.6 ± 0.2
Urine Production (ml/24 h) 13.56 ± 1.16 32.79 ± 1.48# 14.35 ± 0.66 34.09 ± 1.40*
Plasma glucose (mmol/l) 13.72 ± 1.47 12.31 ± 0.90 13.72 ± 0.57 12.62 ± 0.87
Plasma sodium (mmol/l) 138.83 ± 1.05 138.88 ± 0.34 139.30 ± 0.36 140.00 ± 0.47
Plasma potassium (mmol/l) 5.08 ± 0.25 4.80 ± 0.12 4.83 ± 0.07 4.79 ± 0.08
Glucose excretion (mmol/day) 0.01 ± 0.01 8.98 ± 0.84# 0.01 ± 0.00 11.07 ± 0.92*
Sodium excretion (mmol/day) 1.93 ± 0.08 2.87 ± 0.15# 1.85 ± 0.15 3.13 ± 0.17*
Haematocrit (l/l) 45.85 ± 1.39 48.81 ± 0.90 48.42 ± 1.05 49.16 ± 0.71
Insulin/glucagon ratio 4.15 ± 0.77 1.65 ± 0.22# 4.42 ± 0.78 1.66 ± 0.10*
Data are presented as means ± SEM
*p < 0.05 vs. MI-Veh; # p < 0.05 vs. Sham-Veh
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diabetes [23] and we also detected a small increase in plasma
magnesium levels in the EMPA-treated sham and MI groups
(Fig. 3e).
Effects of EMPA on Phosphate Homeostasis
Phosphate homeostasis is regulated by a complex process in-
volving intestinal, renal and bone handling [24]. Plasma phos-
phate plays an essential role on bone health [25]. It has been
suggested that SGLT2 inhibitors stimulate diabetes-related
bone resorption and can increase the fracture-risk in patients
with diabetes [7, 26]. To assess whether this occurs in non-
diabetic rats with HF, we evaluated several parameters of
phosphate homeostasis namely plasma levels of PTH and
FGF23 as well as the renal expression of Klotho and renal
type 2a sodium–phosphate co-transporter (NaPi-2a).
EMPA increased plasma phosphate levels by 8% (Fig. 4a)
and increased the urinary excretion of phosphate (Fig. 4b).
Furthermore, EMPA increased circulating PTH levels (Fig.
4c). Plasma levels of FGF23 were not affected by EMPA
(Fig. 4d), nor was kidney expression of Klotho (Fig. 4e) and






































Fig. 1 Effect of empagliflozin on parameters of renal structure. aRatio of
wet kidney weight to tibia length; n = 8–24/group. b 24-h urinary protein
excretion; n = 8–24/group. c Representative images of PAS-stained
kidney sections (scale bar 100 μm); n = 8/group. Veh, vehicle; EMPA,
empagliflozin. Data are presented as means ± SEM. *p < 0.05 vs. MI-
Veh; #p < 0.05 vs. Sham-Veh
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EMPA had no effect on bone mineral resorption marker CTX-
1 in both sham and MI animals. These findings suggest that
EMPAmarginally increases plasma phosphate and PTH levels
without affecting FGF23–Klotho axis thus does not affect
bone resorption in a non-diabetic setting.
Discussion
We previously discovered that the anti-diabetic drug EMPA
improves cardiac function in non-diabetic rats with HF after
MI, suggesting that it may also benefit non-diabetic HF pa-
tients. In the current analysis, we aimed to determine the renal
effects of EMPA in non-diabetic HF and were able to demon-
strate that (1) the beneficial effects of EMPA on cardiac func-
tion and remodelling were not offset by detrimental conse-
quences on renal structure and function. (2) The marked di-
uretic effects of EMPAwere not associated with severe plasma
volume contraction, nor did EMPA alter plasma levels of
glucose and (most) electrolytes. (3) Structural, functional
and molecular analyses did not provide any suggestion for
EMPA-induced (long term) renal damage in rats with or with-
out HF. (4) EMPA increased circulating magnesium levels. (5)
EMPA increased circulating phosphate and PTH levels with-
out activating the FGF23–Klotho axis. Accordingly, EMPA
did not promote bone mineral resorption. These findings sug-
gest that the beneficial effect of EMPA in non-diabetic HF are
not offset by renal side effects or an increased fracture risk.
Renal dysfunction is common in HF [27], and worsening
renal function (WRF) has been associated with mortality and
HF hospitalisations [17]. Moreover, HF has been associated
with elevated galectin-3 that play a central role in both heart
and kidney fibrosis [28, 29]. Congestion is one of the clinical
hallmarks of HF and congestion can also promote renal dys-
function [30, 31]. HF patients are often treated with diuretics
to prevent or treat congestion, but little is known about their
effect on prognosis [16, 32]. In high doses, diuretics activate
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Fig. 2 Effect of empagliflozin on markers of kidney damage. a
Measurements of mRNA levels to assess molecular markers for kidney
injury; n = 8–24/group. b Measurements of mRNA levels to assess
molecular markers for fibrosis; n = 8–24/group. c Measurements of
mRNA levels to assess molecular markers for inflammation; n = 8–24/
group. dMeasurements of mRNA levels to assess molecular markers for
oxidative stress; n = 8–24/group. Veh, vehicle; EMPA, empagliflozin.
Data are presented as means ± SEM. *p < 0.05 vs. MI-Veh; #p < 0.05
vs. Sham-Veh














































































Fig. 3 Effect of empagliflozin on renal function, magnesium, calcium
and c-terminal telopeptide of type 1 collagen (CTX). a Plasma urea;
n = 8–24/group. b Creatinine clearance of all groups; n = 8–24/group. c
Plasma calcium; n = 8–24/group. d Plasma uric acid; n = 8–24/group. e
Plasma magnesium; n = 8–24/group. f Plasma C-terminal telopeptide of
type I collagen (CTX-1); n = 8–12/group. Veh, vehicle; EMPA,
empagliflozin. Data are presented as means ± SEM. *p < 0.05 vs. MI-



























































































Fig. 4 Effect of empagliflozin on phosphate homeostasis. a Plasma
phosphate; n = 8–24/group. b Urinary phosphate excretion; n = 8–24/
group. c Plasma parathyroid hormone (PTH); n = 8–12/group. d Plasma
fibroblast growth factor 23 (FGF23); n = 8–12/group. e mRNA levels of
Klotho; n = 8–24/group. f mRNA levels of type IIa sodium–phosphate
co-transporter (NaPi-2a); n = 8–24/group. Veh, Vehicle; EMPA,
empagliflozin. Data are presented as means ± SEM. *p < 0.05 vs. MI-
Veh; #p < 0.05 vs. Sham-Veh
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thereby promote HF progression [33, 34]. Furthermore, di-
uretics can cause plasma volume contraction, worsen renal
function and can cause various electrolyte disturbances in-
cluding hypokalemia, hypomagnesemia, hypocalcemia,
hyponatremia and hyperuricemia [35–37]. While mineralo-
corticoid receptor antagonists (MRAs) have mild diuretic ef-
fects and do improve prognosis in HF with reduced ejection
fraction (EF) [38], hyperkalemia and WRF are common side
effects of these drugs as well [39]. Our findings showed that
the potent diuretic effects of EMPA are not accompanied by
renal dysfunction and electrolyte imbalance are reassuring,
and SGLT2i may offer a safe opportunity to alleviate
congestion.
An emerging hypothesis is that SGLT2i may directly in-
hibit the Na+/H+ exchanger isoform 1 (NHE1) in the myocar-
dium and NHE isoform 3 (NHE3) in the kidney [40–43]. It is
thought that the suppression of NHE1 by SGLT2i reduces
cardiac, injury, hypertrophy and fibrosis as well as reduce in
the risk of cardiovascular death and hospitalization for heart
failure [40, 41], and AMPK might also mediate indirect
SGLT2i–NHE interactions in the heart [44], whereas the sup-
pression of NHE3, which is increased in HF, leads to the
inhibition of proximal tubular reabsorption of sodium and
thereby decreasing intravascular volume and cardiac wall
stress [40, 41, 45]. Thus, inhibition of NHE1 and NHE3
may be beneficial to prevent and/or treat heart failure.
The considerable increase in diuresis observed with
SGLT2i suggests that these drugs could be classified as di-
uretics. A study in patients with T2D demonstrated that
SGLT2i dapagliflozin may have a diuretic-like effect beyond
the glycaemic control [46]. The mechanisms of SGLT2i-
mediated diuresis are, however, very different from classical
diuretics prescribed to HF patients. SGLT2i function as os-
motic diuretics and reduce interstitial fluid volume without
causing major changes to plasma volume and sodium levels,
whereas the reverse is true for loop diuretics [47, 48]. Another
difference between SGLT2i and classical diuretics is that
SGLT2i promotes uric acid excretion and may therefore pre-
vent gout [49]. Nevertheless, the cardiovascular benefits of
SGLT2i in high risk exceed the benefits of classical diuretics,
making it highly unlikely that these benefits are merely ex-
plained by enhanced diuresis [50]. Future studies should better
map the interplay and interactions of joint use of thiazides and
loop diuretics and SGLT2i.
The US Food and Drug Administration (FDA) has raised
the concern for acute kidney injury (AKI) associated with
SGLT2i canagliflozin and dapagliflozin use [51]. However,
a longitudinal analysis from two large health system registries,
Mount Sinai chronic kidney disease registry and the Geisinger
Health System cohort, demonstrated that SGLT2i use is not
associated with an increased risk of AKI in patients with T2D
[52]. Furthermore, a study by Cahn et al. confirmed that
SGLT2i do not increase risk for AKI compared with DPP4
inhibitors among patients with T2D [53]. DAPA-HF trial re-
vealed that the beneficial effects of SGLT2i dapagliflozin was
not related to any adverse events on renal function [12]. Our
findings support and extend this observation as we found no
evidence of renal damage, by either functional (plasma urea,
creatinine clearance) or structural (proteinuria, renal histopath-
ological analysis) renal damage after EMPA treatment.
Similarly, we have performed a comprehensive screening of
the relevant markers for kidney injury, fibrosis, inflammation
and oxidative stress, and no significant differences were ob-
served among the various groups, providing molecular proof
that there are no damaging processes occurring in kidneys of
rats treated with SGLT2i.
SGLT2i increases circulating Mg2+ levels in individuals
with T2D, and therefore, it has been proposed that the increase
in circulating Mg2+ could at least partially underlie the cardio-
beneficial effects of SGLT2i [23, 54, 55]. Mg2+ homeostasis is
maintained by the interaction of the intestine, bone and kid-
neys [56, 57]. Several hormones have been suggested to affect
the Mg2+ balance. Studies in rats showed that Mg2+
reabsorptive capacity in the distal segment of the kidney is
increased after glucagon and PTH infusion [58, 59]. Insulin
causes a shift of magnesium from the extracellular to the in-
tracellular space, resulting in a decrease in plasma magnesium
and an increase in erythrocyte magnesium content in both
healthy non-diabetics and diabetic individuals [60, 61]. In
our study, we observed that EMPA reduced insulin/glucagon
ratio (Table 2) and increased PTH levels in plasma (Fig. 4c).
Building upon these observations, our data suggest that in-
creases in plasma magnesium levels are most probably ex-
plained by the effects of EMPA on insulin, glucagon and PTH.
Our observation demonstrated that EMPA caused a slight
but significant increase in serum phosphate and PTH concen-
trations and is in line with similar observations in patients with
or without diabetes [62–64]. The increase in PTH levels has
raised the concern that SGLT2i may promote bone mineral
resorption and increase fracture risk [62]. The putative mech-
anisms are sought in the fact that SGLT2i increase tubular
sodium concentrations and increase renal phosphate reabsorp-
tion through enhanced activity of sodium–phosphate co-
transporter (NaPi) [62]. The resultant increase in plasma phos-
phate levels will then trigger a reactive increase in PTH secre-
tion by the parathyroid gland and the secretion of FGF23 by
osteocytes. PTH and FGF-23 promote bone resorption and
reduce bone mineralisation, respectively, and are both impli-
cated in osteoporosis [24, 65]. Furthermore, both factors sup-
press the activity of NaPi-2a and NaPi-2c in the kidney which
promotes urinary phosphate excretion [66]. A study by Weir
et al. demonstrated that in patients with T2D receiving
SGLT2i canagliflozin versus placebo, minimal increases in
serum phosphate and magnesium were within normal limits
and has no clinical relevance [67]. While we did observe an
increase in plasma phosphate and PTH levels, the observed
Cardiovasc Drugs Ther (2020) 34:311–321318
changes were within physiological range [68]. Furthermore,
calcium levels were unaltered and we did not find evidence for
enhanced bone resorption. Plasma FGF23 and renal expres-
sion of NaPi-2a were also unaltered, indicating that EMPA did
not result in the activation of the FGF-23–Klotho axis. In
addition, no effect on plasma CTX-1 was noted in both vehi-
cle and EMPA-treated animals. These results are in contrast
with observations by Thraikill et al., who studied a model for
diabetic bone disease [7]. Our findings are also in line with
recent evidence that demonstrated that SGLT2i do not result in
a net increase in fracture risk [69, 70]. Taken together, our data
suggest that EMPA does not affect the bonemineral resorption
in a non-diabetic context.
Study Limitations
Despite strengths related to the direct measures of renal struc-
ture, function and other physiological parameters, our study
does have limitations. In addition to the inherent limitations
associated with our experimental heart failure model and dif-
ferences among species, there are a number of specific limita-
tions to our study. First, in accordance with the previous stud-
ies, our post-MI HFmodel did not induce renal dysfunction in
rats [71, 72]. Our findings may therefore not reflect the effects
of EMPA in patients with both cardiac and renal dysfunction.
Second, we compared EMPA with placebo in this study and
therefore cannot extrapolate whether there will be a meaning-
ful interaction with other HF drugs, including diuretics. Third,
our study was not focussed on bone health and we did not
perform direct measurements of bone mineral density.
Nevertheless, our study does provide compelling evidence
suggesting that the cardiac benefits of EMPA are not associ-
ated with detrimental renal consequences or impediments in
bone health. Another potential limitation of our study was the
exclusion of 20 rats with small infarctions because their car-
diac function is close to normal. As a sensitivity analysis we
performed all analyses both with and without rats with small
infarctions, and no differences in the outcomes were observed
(data not shown). Further research is clearly required to ascer-
tain whether the improvement of cardiac function was associ-
ated with diuretic properties of EMPA treatment or improve-
ment of cardiac function caused the diuresis.
Conclusion
SGLT2 inhibition with EMPA exerts profound diuretic effects
without compromising renal structure and function or causing
significant electrolyte imbalance. The slight increase in circu-
lating phosphate and PTH after EMPA treatment was not as-
sociated with evidence for increased bone mineral resorption
suggesting that EMPA does not affect bone health.
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